ReviewHuman antibodies2019
Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives.
Review in Human antibodies, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients.Frontiers in immunology · 2026Article
- The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy.Journal of inflammation research · 2025Review
- Article
- Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.Cureus · 2024Review
- Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.Life (Basel, Switzerland) · 2023Review
- Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases.Journal of clinical medicine · 2023Review
- Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021.Biomedicines · 2022Review
- Therapeutic Antibodies: An Overview.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4.Molecular therapy oncolytics · 2021Article
- From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review.Frontiers in veterinary science · 2021Review
- A new era for monoclonal antibodies with applications in neurology (Review).Experimental and therapeutic medicine · 2021Review
- Review
- Selected Biological Medicinal Products and Their Veterinary Use.Animals : an open access journal from MDPI · 2020Review
- Opinion: Standardizing the definition of gene drive.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Germinality does not necessarily define mAb expression and thermal stability.Applied microbiology and biotechnology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nomenclature of monoclonal antibodies traditionally followed a strict scheme indicating target and species information. Because of the rapid advances in this field, emphasized by approval of four humanized and six human antibodies in 2017, the International Nonproprietary Name of new antibodies was updated profoundly by removing the species substem completely. In this review we give an overview about what developments led to the preference of the scientific community towards human-like antibodies. We summarize the major updates in naming schemes that tried to classify antibodies according to their humanization technique or to the final primary sequence and how this led to the erroneous perception to indicate expected immunogenicity. Following the new 2017 nomenclature update, there will not be any information available about the species origin in the names of new antibodies, which emphasizes the need for providing additional supplemental information to the scientific community and develop tools to accurately estimate and control the safety of new monoclonal antibody molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.